Table 1.
Study group characteristics n (%)
| Cancer | Control | Significance | |
| Male | 36 (82) | 38 (65) | |
| Female | 8 (18) | 20 (35) | |
| Age (yr) | 69 ± 12 | 64 ± 12 | P = 0.230 |
| Folate level | P = 0.735 | ||
| Normal | 26 (84) | 42 (82) | |
| Low | 0 | 8 (16) | |
| High | 5 (16) | 1 (2) | |
| Vitamin B12 level | P = 0.010 | ||
| Normal | 23 (72) | 48 (89) | High vs normal + low |
| Low | 1 (3) | 4 (7) | |
| High | 8 (25) | 2 (4) | |
| Homocysteine level μmol/L | 10.3 ± 4.4 | 12.0 ± 6.0 | P = 0.959 |
| MTHFR C677T | Total TT vs CT and CC | ||
| TT | 5 (11) | 4 (7) | P = 0.329 |
| CT | 20 (46) | 27 (47) | |
| CC | 19 (43) | 27 (47) | |
| MTHFR C677T | Normal folate | Low folate | High folate |
| TT | 3 (10) | 0 | 0 |
| CT | 11 (36) | 0 | 1 (3) |
| CC | 12 (38) | 0 | 4 (13) |
| Survival (mo) | P = 0.160 | ||
| TT | 7 ± 1.4 | TT vs CT + CC | |
| CT | 17 ± 4.4 | ||
| CC | 21 ± 7.0 |
The characteristics of the cancer and control groups are displayed, patient numbers are shown and percentages or SD are indicated in brackets. The gender and average age of the study population at the time of study are shown. Mean levels of homocysteine are presented with standard deviations in brackets. Methylene tetra-hydrofolatereductase (MTHFR) C667T polymorphisms, TT, CT and CT were determined, the percentage in the cancer and control groups are displayed. Mean survival times in months and standard errors are displayed.